Table 2.
Week 48 efficacy (NC = M) | ETV (n = 159) | LAM (n = 146) |
Serum HBV DNA, mean ± SE, change from baseline log10 IU/mL | -6.85 ± 0.16 | -5.30 ± 0.22 |
Knodell necroinflammatory score, mean ± SE change from baseline | -3.4 ± 0.26 | -3.0 ± 0.29 |
Ishak fibrosis score, mean ± SE change from baseline | -0.5 ± 0.08 | -0.3 ± 0.08 |
NC = M: Non-completer = missing; ETV: Entecavir; LAM: Lamivudine.